about
RUNX1 regulates the CD34 gene in haematopoietic stem cells by mediating interactions with a distal regulatory elementCombined Population Dynamics and Entropy Modelling Supports Patient Stratification in Chronic Myeloid LeukemiaA novel mouse model identifies cooperating mutations and therapeutic targets critical for chronic myeloid leukemia progression.Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry.The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF).Mouse models as tools to understand and study BCR-ABL1 diseases.Endoplasmic reticulum protein GliPR1 regulates G protein signaling and the cell cycle and is overexpressed in AML.Characterization of ZC3H15 as a potential TRAF-2-interacting protein implicated in the NFκB pathway and overexpressed in AML.Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both.Contemporary insights into the pathogenesis and treatment of chronic myeloproliferative neoplasms.Epigenetic biomarker to support classification into pluripotent and non-pluripotent cells.Up-regulated MSI2 is associated with more aggressive chronic myeloid leukemia.A 'telomere-associated secretory phenotype' cooperates with BCR-ABL to drive malignant proliferation of leukemic cells.Perioperative intravenous immunoglobulin treatment in a patient with severe acquired von Willebrand syndrome: case report and review of the literature.Long-term results of a prospective randomized trial evaluating G-CSF priming in intensive induction chemotherapy followed by autologous stem cell transplantation in elderly patients with acute myeloid leukemia.Health care setting and severity, symptom burden, and complications in patients with Philadelphia-negative myeloproliferative neoplasms (MPN): a comparison between university hospitals, community hospitals, and office-based physicians.The kinase defective EPHB6 receptor tyrosine kinase activates MAP kinase signaling in lung adenocarcinoma.Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling.Epimutations mimic genomic mutations of DNMT3A in acute myeloid leukemia.Mtss1 is a critical epigenetically regulated tumor suppressor in CML.The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark surveyBCP-ALL blasts are not dependent on CD19 expression for leukaemic maintenance.Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms.Molecular monitoring in NUP214-ABL-positive T-acute lymphoblastic leukemia reveals clonal diversity and helps to guide targeted therapy.Leukocyte Counts Based on DNA Methylation at Individual Cytosines.Epigenetic dysregulation in chronic myeloid leukaemia: A myriad of mechanisms and therapeutic options.Bone marrow laminins influence hematopoietic stem and progenitor cell cycling and homing to the bone marrow.Patient-customized Drug Combination Prediction and Testing for T-cell Prolymphocytic Leukemia Patients.Telomere length at diagnosis of chronic phase chronic myeloid leukemia (CML-CP) identifies a subgroup with favourable prognostic parameters and molecular response according to the ELN criteria after 12 months of treatment with nilotinib.Modelling IRF8 Deficient Human Hematopoiesis and Dendritic Cell Development with Engineered iPS Cells.Mtss1(CSC156) mutant mice fail to display efficient Mtss1 protein depletion.Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasms.Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.Gab2 is essential for Bcr-Abl-mediated leukemic transformation and hydronephrosis in a chronic myeloid leukemia mouse model.Low SMC1A protein expression predicts poor survival in acute myeloid leukemia.[Diagnosis and treatment of polycythemia vera in 2015].NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR-ABL-positive mice.Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors.Serum of myeloproliferative neoplasms stimulates hematopoietic stem and progenitor cells.Prophylaxis and management of venous thromboembolism in patients with myeloproliferative neoplasms: consensus statement of the Haemostasis Working Party of the German Society of Hematology and Oncology (DGHO), the Austrian Society of Hematology and O
P50
Q24336420-30DA49C2-A552-485F-AAF0-E279872AC247Q34521001-054A2BA0-53B3-4843-89C0-4BA9A49F7959Q36080675-B0D1F6D4-C03D-454A-96AE-448E33016E3AQ36654317-4B50C3D2-4C4E-4C4B-8305-B33C3A1A464FQ37561170-FBE37622-6112-447A-9BEF-AD29BD6AEA9EQ37995194-3DD5AA40-6692-40F7-96DD-54F74454BC0EQ38486117-58C543D8-BA70-473A-B470-220B2B0EB2CFQ38490640-14ADE9A8-87E7-4E7F-800B-7F2D5488B8C8Q38725723-7F37DC04-FC54-45F6-A823-65B06B466C2DQ38848273-EEFCDCE7-6DDF-43BB-8765-491663B70179Q38901846-7D067028-309D-45CD-82CF-4692ABE0B06FQ38943340-FA4E5CAA-CAE7-4CD7-B4D0-A1A52CF59975Q39017947-D049D0B4-1C02-4E47-B627-77D51B96FE90Q39282205-81AFB62C-10BE-4F32-9AE2-026EE4375062Q39361086-6ED4D368-70CA-45BA-80DB-F44569BE38BDQ39661740-AEB1F3C7-EAC2-4A9E-805D-8FD87F1CF413Q39840152-130F902A-39DE-4AF1-B654-171B627BC8EEQ40095304-FB375D6A-5213-4C28-844B-3A48E633ACFCQ40503875-E58881D5-D4C2-494E-AD17-9CD992C9ADC8Q41085680-8AAEAF0D-DD21-4AC5-9F6A-848D8F12BF52Q41508203-84F71431-4830-4085-B20E-8DD39A1E4FAEQ41979757-9D5FC0AA-8DF8-45CC-BADD-A12348BFE162Q46282374-1FD32FF9-E197-41DD-B840-F02EC6CF9C18Q46416550-43F0329A-DBE0-44A7-9181-7660D31A9ED2Q47368072-B0BD4044-79EE-4BAE-AAB3-5E88E7492C72Q47990195-4A5BB348-D028-43C6-A6A2-829C770ECE56Q49841243-B85C1825-95E7-4D60-93E2-CBD1FEBE65E4Q50421801-88C6DF48-4D76-48DB-BABA-261D0F6E1778Q50561494-1686865F-8E8D-47F6-BA5D-44167189FC59Q51043236-82F17A1F-0F2B-452C-AD17-1F8467AED69CQ51149597-3398F92C-4852-4833-BA0D-8DC5FE787FBEQ51368335-D41C2621-27E8-4071-9FC5-B7CB2FDCE9D6Q52668513-1D5E1EC8-B585-498C-B8D2-662AACC311F1Q53202732-5D06AD68-40D5-4C90-AE11-FE80BDF6FDD5Q53321036-798DAAE3-C7A4-42D9-B37F-A43F0424876FQ54241864-658AFECD-425E-46DA-B5B2-018960116DF0Q54561974-F486845B-2D0F-47BE-BB00-BEFAB91A27B9Q54978631-78217FEF-3998-4D38-8885-34D8D9586873Q55334343-F16B20C3-4225-42B6-8014-9D33272E14AEQ56960816-E910DE6B-B049-4AA1-87CF-D1B2751761EB
P50
description
Forscher
@de
chercheur
@fr
investigador
@es
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
研究者
@zh
name
Steffen Koschmieder
@ast
Steffen Koschmieder
@en
Steffen Koschmieder
@es
Steffen Koschmieder
@nl
type
label
Steffen Koschmieder
@ast
Steffen Koschmieder
@en
Steffen Koschmieder
@es
Steffen Koschmieder
@nl
prefLabel
Steffen Koschmieder
@ast
Steffen Koschmieder
@en
Steffen Koschmieder
@es
Steffen Koschmieder
@nl
P31
P496
0000-0002-1011-8171